Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mereo BioPharma Group PLC

MREO ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.24

▲ +0.87%

Market Cap $39.06M · Vol 193.11K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$39.06M

Micro Cap

Div Yield

N/A

EPS Growth

+30.00%

YoY

RSI (14)

29.79

Momentum

Beta

0.22

vs Market

52W High

$2.37

89.68% below

52W Low

$0.20

22.30% above

Volume

193.11K

Avg 410.01K

P/B

1.62

Price-to-book

ROE

-82.21%

Return on equity

Free Float

99.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mereo BioPharma Group PLC (MREO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MREO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.46%

-10.21%

-19.72%

-38.80%

YTD

-41.30%

-86.26%

-82.28%

-90.77%

Financials & Valuation

TTM · Annual

Total Revenue	$500.00K
Net Income	$-41,878,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	73.40%
Operating Margin	-8,021.40%
Net Profit Margin	-8,375.60%
ROE	-82.21%
ROA · ROIC	-68.48% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	132.86
P/B	1.62
P/FCF	N/A
EPS Growth	+30.00%
Outstanding Shares	798.45M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.55
RSI (14)	29.79
Beta	0.22
52-Week High	$2.37
52-Week Low	$0.20

Volume Today	193.11K
Avg Daily Volume (30D)	410.01K
Relative Volume	0.47x
Volatility (10D)	71.26
Volatility (30D)	75.17
Free Float	99.25%

Analyst Consensus

BUY

Current Price $0.24

Mean Target $1.75

52W Low$0.20 52W High$2.37

Current

Target

$0.20 $2.37

Current Analyst target

+615.45% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00KFWZCX7

ISINUS5894921072

CountryUK

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.14% ARGX.BR argenx SE -1.09% ARGX argenx SE -1.82% INSM Insmed Incorporated -1.18% 2269.HK WuXi Biologics (Cayman) Inc. -2.74%

Company Profile

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.